ImmunoVec
ImmunoVec is a preclinical-stage biotechnology company developing in vivo cell engineering therapies using DNA-loaded polymeric nanoparticles and cell type-specific synthetic promoters to treat autoimmune diseases, solid tumors, and genetic immune disorders.
- Company typePrivate
- Founded2025
- HeadquartersSanta Monica, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImmunoVec does
ImmunoVec is a preclinical-stage biotechnology company developing in vivo cell engineering therapies for autoimmune diseases, solid tumors, and genetic disorders of the immune system. Founded in 2019 and headquartered at the California NanoSystems Institute (CNSI) in Los Angeles, the company emerged from stealth mode in October 2025 with 1-10 employees. Its therapeutic candidates are designed to reprogram immune cells directly within the patient, eliminating the need for ex vivo cell manufacturing associated with current CAR-T and gene therapy approaches.
The company's core platform is a dual-precision system that pairs DNA-loaded biodegradable polymeric nanoparticles with proprietary cell type-specific synthetic promoters. The nanoparticle vehicle delivers DNA payloads to targeted cell populations, and the synthetic promoters restrict expression of the therapeutic payload to the intended cell types only. The platform is explicitly delivery-vehicle agnostic, supporting both viral (lentivirus/retrovirus, AAV, viral-like particles) and non-viral (polymeric nanoparticles, lipid nanoparticles, exosomes) systems. The disclosed pipeline includes a lead CD19-targeted CAR NK cell therapy for B-cell-driven autoimmune diseases, plus preclinical programs in X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome, and IPEX syndrome, with a stated intent to extend into solid tumor indications.
ImmunoVec is pre-revenue. Its business model is predicated on long-cycle therapeutic development and eventual commercialization of proprietary in vivo cell therapies, with near-term economics driven by non-dilutive grant funding rather than product sales. To date, the company has secured approximately $4.0 million from the California Institute for Regenerative Medicine (May 2025) and an up to $40.7 million ARPA-H EMBODY award (September/October 2025), alongside an earlier 2022 round of approximately $4.3 million. The company is sales-led in the sense of pursuing strategic research collaborations and grant capture — currently with Johns Hopkins University and MD Anderson Cancer Center — and is actively pursuing a Series A financing to accelerate pipeline development through first-in-human clinical trials.
ImmunoVec firmographics
Firmographics- Name
- ImmunoVec
- Legal name
- ImmunoVec Inc
- Website
- https://immunovec.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImmunoVec is a preclinical-stage biotechnology company developing in vivo cell engineering therapies using DNA-loaded polymeric nanoparticles and cell type-specific synthetic promoters to treat autoimmune diseases, solid tumors, and genetic immune disorders.
- Ownership category
- akta.pro rank
ImmunoVec industry classification
Industry- Product category
- Cell and Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), NK Cell Therapies (HLAAABAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where ImmunoVec is headquartered
LocationHeadquarters
- HQ city
- Santa Monica
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
ImmunoVec business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Therapeutic Product Development and Commercialization: Developing novel cell and gene therapies targeting autoimmune diseases, solid tumors, and genetic disorders. Revenue expected from clinical development and eventual commercialization of proprietary therapies.
Go-to-market motion1 record
Marketing channels4 records
ImmunoVec product offering
Product offeringCore offering
ImmunoVec develops in vivo cell engineering therapies using a proprietary platform that combines DNA-loaded polymeric nanoparticles with cell type-specific synthetic promoters. The platform enables precise reprogramming of immune cells directly inside the human body to treat autoimmune diseases, genetic disorders, and solid tumors. The company's lead therapeutic candidate is a CD19-targeted CAR NK cell therapy for autoimmune disease, complemented by preclinical gene therapy programs for X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome, and IPEX syndrome.
Product overview
ImmunoVec is pioneering the next generation of in vivo cell engineering with a proprietary platform that combines DNA-loaded polymeric nanoparticles with cell type-specific synthetic promoters. The core platform enables precise reprogramming of immune cells directly within the body, offering significant advantages over traditional ex vivo cell therapies. The company is developing multiple therapeutic programs including a CD19-targeted CAR NK cell therapy for autoimmune diseases, along with preclinical programs for pediatric genetic disorders (X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome, IPEX syndrome). The platform supports both viral delivery vehicles (lentivirus, AAV, viral-like particles) and non-viral systems (polymeric nanoparticles, lipids, exosomes), with proprietary expression cassettes ensuring precise expression only in intended cells.
Differentiator
Problem solved
Functional benefit
Products and services
- CD19-Targeted CAR NK Cell Therapy Preclinical in vivo cell therapy candidate that uses ImmunoVec's polymeric nanoparticle platform to engineer NK cells with a CD19-targeted CAR construct, intended to deplete B cells driving autoimmune disease.
- X-Linked Chronic Granulomatous Disease Program Preclinical cell type-specific gene therapy program for X-linked chronic granulomatous disease, a serious pediatric immunodeficiency, with preclinical data showing restoration of normal gene expression.
- Wiskott-Aldrich Syndrome Program Preclinical gene therapy program utilizing ImmunoVec's DNA-loaded polymeric nanoparticle platform to address Wiskott-Aldrich syndrome, a serious pediatric immunodeficiency disorder.
- IPEX Syndrome Program Preclinical gene therapy program targeting IPEX syndrome, a severe pediatric autoimmune disorder caused by genetic mutations affecting immune regulation.
Quantifiable outcome
- Pre-clinical data demonstrate restoration of normal gene expression with potential to safely and effectively reduce or eliminate symptoms of serious illnesses such as X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome, and IPEX syndrome
Companies that use ImmunoVec
Customer profileSegments3 records
Ideal customer profiles2 records
ImmunoVec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
ImmunoVec partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Johns Hopkins UniversitycoreWorld-renowned research institution collaborating with ImmunoVec on the ARPA-H EMBODY project to evaluate the company's DNA-loaded polymeric nanoparticle platform for precisely reprogramming immune cells in patients.
- MD Anderson Cancer CentercoreThe University of Texas MD Anderson Cancer Center collaborating with ImmunoVec on the multi-year ARPA-H EMBODY award project to develop in vivo cell engineering therapies for autoimmune diseases.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
ImmunoVec competitors and assessment
Company assessmentDirect peers
- Capstan Therapeutics: Capstan Therapeutics is a direct competitor developing in vivo cell therapies using lipid nanoparticles to deliver mRNA payloads that reprogram immune cells, including CAR-T approaches for autoimmune disease and cancer. Both companies target the same fundamental opportunity: replacing expensive ex vivo CAR-T with off-the-shelf in vivo cell engineering.
- Umoja Biopharma: Umoja Biopharma is developing in vivo CAR-T cell therapies using viral vector and nanoparticle delivery platforms for cancer and autoimmune disease. Like ImmunoVec, Umoja is pursuing off-the-shelf in vivo cell engineering to overcome the cost and scalability limitations of current CAR-T therapies.
- Cabaletta Bio: Cabaletta Bio is developing CAR-T cell therapies specifically for autoimmune diseases, including CD19-directed approaches. They are a direct competitor to ImmunoVec's CD19 CAR-NK autoimmune program and represent the kind of established clinical-stage player ImmunoVec will compete against in autoimmune B-cell depletion.
- Kyverna Therapeutics: Kyverna Therapeutics is a clinical-stage cell therapy company developing CAR-T treatments for autoimmune diseases. Like ImmunoVec, Kyverna targets B-cell-driven autoimmune pathology and represents direct competition in the autoimmune CAR-T space where ImmunoVec's CD19 CAR-NK program will compete.
Emerging players
- Strand Therapeutics: Strand Therapeutics develops synthetic biology-based mRNA therapeutics with cell-type specific expression for cancer immunotherapy, partially overlapping with ImmunoVec's approach of cell type-specific payload expression for immune cell programming. Both companies work at the intersection of synthetic promoters and immune cell engineering.
- Laronde (acquired by Locus Biosciences): Laronde pioneered endless RNA (eRNA) for therapeutic protein expression and was acquired by Locus Biosciences. They shared ImmunoVec's vision of durable, in vivo expression of therapeutic payloads with reduced immunogenicity compared to viral vectors, addressing similar programmable expression challenges in cell therapy.
Broad incumbents
- Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-delivered treatments for neurological diseases. While focused on different indications, Voyager competes for the same gene therapy delivery IP and partnerships relevant to ImmunoVec's viral delivery-based programs.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage gene editing company with approved therapy Casgevy. As a broader incumbent in genetic medicine, they represent both a potential competitor in monogenic disease treatment and a likely strategic acquirer of cell engineering platforms like ImmunoVec's.
- Prime Medicine: Prime Medicine is developing prime editing, a next-generation gene editing technology, for genetic diseases. As a broad incumbent in programmable genetic medicine, Prime Medicine is comparable as a potential competitor or partner targeting monogenic immune disorders similar to ImmunoVec's pipeline.
- Moderna: Moderna is a leading mRNA and LNP delivery platform company with significant investment in cell therapy applications and autoimmune disease programs. As a broad incumbent with delivery platform expertise, Moderna could be both a competitor and a potential strategic acquirer of ImmunoVec's cell-type specific expression technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
ImmunoVec social profiles
Digital presenceImmunoVec financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmunoVec leadership team
Management profileNumber of profiles
Profiles4 records
ImmunoVec funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmunoVec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmunoVec
What does ImmunoVec do?
ImmunoVec develops in vivo cell engineering therapies using a proprietary platform that combines DNA-loaded polymeric nanoparticles with cell type-specific synthetic promoters. The platform enables precise reprogramming of immune cells directly inside the human body to treat autoimmune diseases, genetic disorders, and solid tumors. The company's lead therapeutic candidate is a CD19-targeted CAR NK cell therapy for autoimmune disease, complemented by preclinical gene therapy programs for X-linked chronic granulomatous disease, Wiskott-Aldrich syndrome, and IPEX syndrome.
Is ImmunoVec a public or private company?
ImmunoVec is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmunoVec founded?
ImmunoVec was founded in 2025. It employs 11 to 50 people.
Where is ImmunoVec based?
ImmunoVec is headquartered in Santa Monica, United States, in the North America region.
How does ImmunoVec make money?
One revenue line is on record: therapeutic Product Development and Commercialization.
Who are ImmunoVec's main competitors?
Direct peers on record are Capstan Therapeutics, Umoja Biopharma, Cabaletta Bio and Kyverna Therapeutics. Emerging players are Strand Therapeutics and Laronde (acquired by Locus Biosciences). Broad incumbents are Voyager Therapeutics, CRISPR Therapeutics, Prime Medicine and Moderna.
Does ImmunoVec have an API?
No public API is recorded for ImmunoVec.
What industry is ImmunoVec in?
ImmunoVec's product category is Cell and Gene Therapy. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.